Modality
mAb
MOA
TROP-2 ADC
Target
SHP2
Pathway
STING
Ewing SarcomaEpilepsy
Development Pipeline
Preclinical
~Jul 2020
→ ~Oct 2021
Phase 1
Jan 2022
→ May 2030
Phase 1Current
NCT06110519
118 pts·Ewing Sarcoma
2025-10→2029-08·Not yet recruiting
NCT03837047
198 pts·Epilepsy
2022-01→2030-05·Not yet recruiting
316 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-08-083.4y awayPh2 Data· Ewing Sarcoma
2030-05-054.1y awayPh2 Data· Epilepsy
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1/2
Not yet…
P1/2
Not yet…
Catalysts
Ph2 Data
2029-08-08 · 3.4y away
Ewing Sarcoma
Ph2 Data
2030-05-05 · 4.1y away
Epilepsy
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06110519 | Phase 1/2 | Ewing Sarcoma | Not yet recr... | 118 | CfB |
| NCT03837047 | Phase 1/2 | Epilepsy | Not yet recr... | 198 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| MRN-7409 | Moderna | NDA/BLA | SHP2 | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 |